Hepatitis B vaccination of adolescents: Significance of non-protective antibodies

Vaccine

Volumn 32, Issue 1, 2013, Pages 62-68

  Chiara, Federica ^a   Bartolucci, Giovanni Battista ^a   Cattai, Margherita ^a   Piazza, Anna ^a   Nicolli, Annamaria ^a   Buja, Alessandra ^a   Trevisan, Andrea ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Anti HBs; Booster vaccination; Hepatitis B; Persistence of antibodies; Protective antibodies; Vaccination

Indexed keywords

HEPATITIS A HEPATITIS B VACCINE; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B VACCINE; RECOMBINANT HEPATITIS B VACCINE;

ADOLESCENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; IMMUNE RESPONSE; INFECTION RESISTANCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VACCINATION;

ANTI-HBS; BOOSTER VACCINATION; HEPATITIS B; PERSISTENCE OF ANTIBODIES; PROTECTIVE ANTIBODIES; VACCINATION;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CHILD; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; IMMUNIZATION, SECONDARY; MALE; ROC CURVE; VACCINATION; YOUNG ADULT;

EID: 84891929415     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.10.074     Document Type: Article

References (32)

1. Legge 27 maggio 1991, n. 165: Obbligatorietà della vaccinazione contro l'epatite virale B. [Law May 27 1991, No. 165: Compulsory vaccination against hepatitis B virus].
2. Circolare 4 ottobre 1991, n. 20: Disposizioni relative all'applicazione della legge 27 maggio 1991, n. 165. [Circular October 4, 1991, No. 20: Disposition relating to the application of the law of 27 May 1991 No. 165.].
3. Stroffolini T., Mele A., Tosti M.E., Gallo G., Balocchini E., Ragni P., et al. The impact of the hepatitis B mass immunisation campaign on the incidence and risk factors of acute hepatitis B in Italy. J Hepatol 2000, 33:980-985.
4. Zanetti A.R., Mariano A., Romanò L., D'Amelio R., Chironna M., Coppola R.C., et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 2005, 366:1379-1384.
5. Zipp F., Weil J.G., Einhäupl K.M. No increase in demyelinating diseases after hepatitis B vaccination. Nat Med 1999, 5:964-965.
6. Confavreux C., Suissa S., Saddier P., Bourdes V., Vukusic S. Vaccinations and the risk of relapse in multiple sclerosis. N Engl J Med 2001, 344:319-326.
7. Farez M.F., Correale J. Immunizations and risk of multiple sclerosis: systematic review and meta-analysis. J Neurol 2001, 258:1197-1206.
8. Floreani A., Baldo V., Cristofoletti M., Renzulli G., Valeri A., Zanetti C., et al. Long-term persistence of anti-HBs after vaccination against HBV: an 18 year experience in health care workers. Vaccine 2004, 22:607-610.
9. Gabbuti A., Romanò L., Blanc P., Meacci F., Amendola A., Mele A., et al. Long-term immunogenicity of hepatitis B vaccination in a cohort of Italian healthy adolescents. Vaccine 2007, 25:3129-3132.
10. Poovorawan Y., Chongsrisawat V., Theamboonlers A., Bock H.L., Leyssen M., Jacquet J.-M. Persistence of antibodies and immune memory to hepatitis B vaccine 20 years after infant vaccination in Thailand. Vaccine 2010, 28:730-736.
11. Advisory Committee on Immunization Practices; Centers for Disease Control and Prevention (CDC) Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011, 60(RR-7):1-45.
12. European Consensus Group on Hepatitis B Immunity Are booster immunisations needed for lifelong hepatitis B immunity?. Lancet 2000, 355:561-565.
13. Bauer T., Jilg W. Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. Vaccine 2006, 24:572-577.
14. Decreto Legislativo 9 aprile 2008, n. 81: Testo unico sulla salute e sicurezza sul lavoro. [Legislative Decree 9 April 2008, No. 81: Consolidation Act on health and safety at work].
15. Liao S.S., Li R.C., Li H., Yang J.Y., Zeng X.J., Gong J., et al. Long-term efficacy of plasma-derived hepatitis B vaccine: a 15-year follow-up study among Chinese children. Vaccine 1999, 17:2661-2666.
16. McMahon B.J., Bruden D.L., Petersen K.M., Bulkow L.R., Parkinson A.J., Nainan O., et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med 2005, 142:333-341.
17. Alfaleh F., Alshehri S., Alansari S., Aljeffri M., Almazrou Y., Shaffi A., et al. Long-term protection of hepatitis B vaccine 18 years after vaccination. J Infection 2008, 57:404-409.
18. Alimonos K., Nafziger A.N., Murray J., Bertino J.S. Prediction of response to hepatitis B vaccine in health care workers: whose titers of antibody to hepatitis B surface antigen should be determined after a three-dose series, and what are the implications in terms of cost-effectiveness?. Clin Infect Dis 1998, 26:566-571.
19. Averhoff F., Mahoney F., Coleman P., Schatz G., Hurwitz E., Margolis H. Immunogenicity of hepatitis B Vaccines. Implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med 1998, 15:1-8.
20. Keating G.M., Noble S. Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B. Drugs 2003, 63:1021-1051.
21. Zanetti A.R., Romanò L., Giambi C., Pavan A., Carnelli V., Baitelli G., et al. Hepatitis B immune memory in children primed with hexavalent vaccines and given monovalent booster vaccines: an open-label, randomised, controlled, multicentre study. Lancet Infect Dis 2010, 10:755-761.
22. Chiara F., Bartolucci G.B., Mongillo M., Ferretto L., Nicolli A., Trevisan A. Hepatitis B vaccination at three months of age: a successful strategy?. Vaccine 2013, 31:1696-1700.
23. Gasparini R., Pozzi T., Montomoli E., Fragapane E., Civai R., Mara E. Vaccination against hepatitis B - Lenght of protection among population risk. J Prev Med Hyg 1998, 39:37-41.
24. Boxall E.H., Sira J.A., El-Shuhkri N., Kelly D.A. Long-term persistence of immunity to hepatitis B after vaccination during infancy in a country where endemicity is low. J Infect Dis 2004, 190:1264-1269.
25. Fitzsimons D., François G., Hall A., McMahon B., Meheus A., Zanetti A., et al. Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. Vaccine 2005, 23:4158-4166.
26. Leroux-Roels G., Van Hecke E., Michielsen W., Voet P., Hauser P., Pêtre J. Correlation between in vivo humoral and in vitro cellular immune responses following immunization with hepatitis B surface antigen (HBsAg) vaccines. Vaccine 1994, 12:812-818.
27. Wu J.S., Hwang L.-Y., Goodman K.J., Beasley R.P. Hepatitis B vaccination in high-risk infants: 10-year follow-up. J Infect Dis 1999, 179:1319-1325.
28. Spradling P.R., Xing J., Williams R., Masunu-Faleafaga Y., Dulski T., Mahamud A., et al. Immunity to hepatitis B virus infection two decades after implementation of universal infant hepatitis B vaccination: the association of detectable residual antibody and response to a single hepatitis B vaccine challenge dose. Clin Vaccine Immunol 2013, 20:559-561.
29. Jan C.F., Huang K.C., Chien Y.C., Greydanus D.E., Davies H.D., Chiu T.Y., et al. Determination of immune memory to hepatitis B vaccination through early booster response in college students. Hepatology 2010, 51:1547-1554.
30. Roznovsky L., Orsagova I., Kloudova A., Tvrdik J., Kabieszova L., Lochman I., et al. Long-term protection against hepatitis B after newborn vaccination: 20-year follow-up. Infection 2010, 38:395-400.
31. Carollo M., Palazzo R., Bianco M., Pandolfi E., Chionne P., Fedele G., et al. Hepatitis B specific T cell immunity induced by primary vaccination persists independently of the protective serum antibody level. Vaccine 2013, 31:506-513.
32. Valats J.C., Tuaillon E., Funakoshi N., Hoa D., Brabet M.C., Bolloré K., et al. Investigation of memory B cell responses to hepatitis B surface antigen in health care workers considered as non-responders to vaccination. Vaccine 2010, 28:6411-6416.